Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

Background: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced soft tissue sarcoma (STS) pretreated with DXR. Patients and methods: Patients with measurable and progressive STS received PLD at...

Descripción completa

Detalles Bibliográficos
Autores principales: Poveda, A., López-Pousa, A., Martín, J., Del Muro, J. García, Bernabé, R., Casado, A., Balañá, C., Sanmartín, O., Menéndez, M. D., Escudero, P., Cruz, J., Belyakova, Elena, Menéndez, D., Buesa, J. M.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395634/
https://www.ncbi.nlm.nih.gov/pubmed/18521419
http://dx.doi.org/10.1080/13577140500287024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395634/
https://www.ncbi.nlm.nih.gov/pubmed/18521419
http://dx.doi.org/10.1080/13577140500287024

Ejemplares similares